Theravance Biopharma EPS of -$0.11, revenue of $20.73M misses by $1.59M (TBPH:NASDAQ)
· seekingalpha.com
Theravance Biopharma (TBPH) Q2 earnings: EPS -$0.11 vs consensus, revenue $20.73M miss, and Viatris U.S.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...